126 related articles for article (PubMed ID: 38247066)
41. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial.
Nishimura R; Anan K; Yamamoto Y; Higaki K; Tanaka M; Shibuta K; Sagara Y; Ohno S; Tsuyuki S; Mase T; Teramukai S
Oncol Rep; 2013 May; 29(5):1707-13. PubMed ID: 23446822
[TBL] [Abstract][Full Text] [Related]
43. Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31.
Chumsri S; Li Z; Serie DJ; Mashadi-Hossein A; Colon-Otero G; Song N; Pogue-Geile KL; Gavin PG; Paik S; Moreno-Aspitia A; Perez EA; Thompson EA
J Clin Oncol; 2019 Dec; 37(35):3425-3435. PubMed ID: 31622131
[TBL] [Abstract][Full Text] [Related]
44. Real world initial palliative treatment patterns and clinical outcomes in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A study of the National Cancer Center, China.
Li Y; Mo H; Guan X; Lin S; Wang Z; Chen Y; Chen S; Li Q; Cai R; Wang J; Luo Y; Fan Y; Yuan P; Zhang P; Li Q; Ma F; Xu B
Breast; 2022 Feb; 61():129-135. PubMed ID: 34995922
[TBL] [Abstract][Full Text] [Related]
45. Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients.
Cantini L; Pistelli M; Merloni F; Fontana A; Bertolini I; De Angelis C; Bastianelli L; Della Mora A; Santinelli A; Savini A; Maccaroni E; Diodati L; Falcone A; Berardi R
Clin Breast Cancer; 2020 Feb; 20(1):e89-e98. PubMed ID: 31378534
[TBL] [Abstract][Full Text] [Related]
46. Recovery of menstruation after long-term chemotherapy and endocrine therapy in pre-menopausal patients with breast cancer.
Sakurai K; Enomoto K; Amano S
J Cancer Res Clin Oncol; 2011 Apr; 137(4):615-20. PubMed ID: 20532911
[TBL] [Abstract][Full Text] [Related]
47. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
[TBL] [Abstract][Full Text] [Related]
48. Systematic literature review of clinical trials of endocrine therapies for premenopausal women with metastatic HR+ HER2- breast cancer.
Patterson-Lomba O; Dalal AA; Ayyagari R; Liu O; Dervishi E; Platt E; Chandiwana D; O'Shaughnessy JA
Breast J; 2019 Sep; 25(5):880-888. PubMed ID: 31290203
[TBL] [Abstract][Full Text] [Related]
49. Impact of adjuvant endocrine therapy on prognosis in small hormone receptor-positive, HER2-negative early breast cancer.
Adachi Y; Oze I; Sawaki M; Hattori M; Yoshimura A; Kotani H; Kataoka A; Sugino K; Horisawa N; Ozaki Y; Endo Y; Nozawa K; Takatsuka D; Iwata H
Breast Cancer; 2021 Sep; 28(5):1087-1095. PubMed ID: 33886077
[TBL] [Abstract][Full Text] [Related]
50. Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer.
Turner S; Chia S; Kanakamedala H; Hsu WC; Park J; Chandiwana D; Ridolfi A; Yu CL; Zarate JP; Rugo HS
Oncologist; 2021 Jul; 26(7):e1133-e1142. PubMed ID: 33909934
[TBL] [Abstract][Full Text] [Related]
51. Real-world clinical profile, treatment patterns and patient-reported outcomes in a subset of HR+/HER2- advanced breast cancer patients with poor prognostic factors: data from an international study.
Davie A; Cuyun Carter G; Rider A; Bailey A; Lewis K; Price G; Ostojic H; Ringeisen F; Pivot X
ESMO Open; 2021 Aug; 6(4):100226. PubMed ID: 34371379
[TBL] [Abstract][Full Text] [Related]
52. Outcomes of male patients with HR+/HER2- advanced breast cancer receiving palbociclib in the real-world POLARIS study.
Blum JL; DiCristo C; Gordon D; Karuturi MS; Oubre D; Jepsen E; Cuevas J; Lakhanpal S; Montelongo MZ; Zhang Z; Cappelleri JC; Wang Y; Tripathy D
Breast Cancer Res Treat; 2024 Feb; 203(3):463-475. PubMed ID: 37903899
[TBL] [Abstract][Full Text] [Related]
53. Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.
Luen SJ; Asher R; Lee CK; Savas P; Kammler R; Dell'Orto P; Biasi OM; Demanse D; JeBailey L; Dolan S; Hackl W; Thuerlimann B; Viale G; Colleoni M; Regan MM; Loi S
JAMA Oncol; 2018 Oct; 4(10):1335-1343. PubMed ID: 29902286
[TBL] [Abstract][Full Text] [Related]
54. ReCAP: Treatment Patterns and Cost of Care Associated With Initial Therapy Among Patients Diagnosed With Operable Early-Stage Human Epidermal Growth Factor Receptor 2-Overexpressed Breast Cancer in the United States: A Real-World Retrospective Study.
DaCosta Byfield S; Buck PO; Blauer-Peterson C; Poston SA; DaCosta Byfield S; Buck PO; Blauer-Peterson C; Poston SA
J Oncol Pract; 2016 Feb; 12(2):159-67. PubMed ID: 26395563
[TBL] [Abstract][Full Text] [Related]
55. Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.
Regan MM; Francis PA; Pagani O; Fleming GF; Walley BA; Viale G; Colleoni M; Láng I; Gómez HL; Tondini C; Pinotti G; Price KN; Coates AS; Goldhirsch A; Gelber RD
J Clin Oncol; 2016 Jul; 34(19):2221-31. PubMed ID: 27044936
[TBL] [Abstract][Full Text] [Related]
56. Real-world Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Analysis.
Statler AB; Hobbs BP; Wei W; Gupta A; Blake CN; Nahleh ZA
Sci Rep; 2019 Dec; 9(1):18126. PubMed ID: 31792304
[TBL] [Abstract][Full Text] [Related]
57. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.
Klijn JG; Blamey RW; Boccardo F; Tominaga T; Duchateau L; Sylvester R;
J Clin Oncol; 2001 Jan; 19(2):343-53. PubMed ID: 11208825
[TBL] [Abstract][Full Text] [Related]
58. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study.
Vaz-Luis I; Ottesen RA; Hughes ME; Marcom PK; Moy B; Rugo HS; Theriault RL; Wilson J; Niland JC; Weeks JC; Lin NU
Breast Cancer Res; 2012 Oct; 14(5):R129. PubMed ID: 23025714
[TBL] [Abstract][Full Text] [Related]
59. De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial.
Harbeck N; Nitz UA; Christgen M; Kümmel S; Braun M; Schumacher C; Potenberg J; Tio J; Aktas B; Forstbauer H; Grischke EM; Scheffen I; Malter W; von Schumann R; Just M; Zu Eulenburg C; Biehl C; Kolberg-Liedtke C; Deurloo R; de Haas S; Jóźwiak K; Hauptmann M; Kates R; Graeser M; Wuerstlein R; Kreipe HH; Gluz O;
J Clin Oncol; 2023 Aug; 41(22):3796-3804. PubMed ID: 36809046
[TBL] [Abstract][Full Text] [Related]
60. Predictive Value of Molecular Subtypes in Premenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the ABCSG Trial 5.
Bago-Horvath Z; Rudas M; Singer CF; Greil R; Balic M; Lax SF; Kwasny W; Hulla W; Gnant M; Filipits M
Clin Cancer Res; 2020 Nov; 26(21):5682-5688. PubMed ID: 32546648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
